News

As per the decision, the Changzhou FDA is expected to impose a fine of RMB25.6m consisting of penalties and confiscated revenues from previous sales of substandard quality human

MP Biomedicals and Rusnano plan to jointly implement projects focused on anti-aging and increasing in life expectancy, as well as creating the infrastructure for innovations in the area

Astellas Pharma and OSI Pharmaceuticals claimed that the combined company creates an oncology platform supporting Astellas Pharmas’ stated growth strategy. OSI commercialises Tarceva (erlotinib), a cancer medication. As

Emerging World Pharma said that by complying with the WHO manufacturing standards, African Global Pharma will be eligible for various grants and funding. Brandon Keks, president of Emerging

Cadence said that on February 10, 2010, it received a complete response letter from the FDA which indicated that the Ofirmev NDA could not be approved due to

HepaLife Technologies is the developer of HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in

The Urology Company was launched in the second half of 2009 to build a portfolio of approved products to market and distribute into the UK urology market. With

Ivax Diagnostics has posted a net loss of $0.96m for the first quarter 2010, or $0.03 per diluted share, compared $0.46m, or $0.02 per diluted share, for the

BioSante Pharma said that by incorporating 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines. The subsequent cell